Keywords
Eligibility Determination ×
Lymphoma, B-Cell ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

35 Search results.

Eligibility Lymphoma, B-Cell, Lymphoma, Follicular NCT01691898

- 7/22/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan and Evaluation of Combination DCDS4501A and Obinutuzumab in Patients With Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01691898

Eligibility Lymphoma, B-Cell, Non-Hodgkin's Lymphoma NCT01724021

- 7/22/20 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Patient Preference With Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Patients With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a; ODM derived from: https://clinicaltrials.gov/show/NCT01724021

Eligibility Lymphoma, B-Cell NCT01649856

- 7/21/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01649856

Eligibility Lymphoma, B-Cell NCT02017613

- 7/21/20 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies; ODM derived from: https://clinicaltrials.gov/show/NCT02017613

Eligibility Lymphoma, B-Cell NCT01287741

- 7/20/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA); ODM derived from: https://clinicaltrials.gov/show/NCT01287741

Eligibility Lymphoma, B-Cell NCT01144403

- 7/18/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.; ODM derived from: https://clinicaltrials.gov/show/NCT01144403

Eligibility Low Grade B Cell Lymphoma NCT01289210

- 7/6/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT01289210

Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516

- 5/1/20 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01933516

Eligibility B-cell Non Hodgkin Lymphoma NCT01516580

- 8/19/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01516580

Eligibility B-cell Non Hodgkin's Lymphoma NCT02206308

- 8/19/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.; ODM derived from: https://clinicaltrials.gov/show/NCT02206308

Eligibility B-Cell Lymphoma Originating in the CNS NCT01235793

- 8/16/19 - 1 form, 2 itemgroups, 31 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory Central Nervous System (CNS) Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01235793

Eligibility B-cell Lymphomas NCT02247609

- 8/16/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT02247609